摘要
许多单一激酶抑制剂的局限性可以通过多靶点抑制剂的应用来克服。靶向多激酶的一个重要的优势是由于协同效应使得效力增加。此外,这种方法可以减少耐药性的发生。一些多靶点药物以前被设计为单一激酶抑制剂,由于ATP结合位点之间的结构同源性而被发现其是多靶点抑制剂。在其他情况下,这些抑制剂已经被有效的单个抑制剂优化或者通过选择性配体的组合而获得。还有一些不可逆抑制剂作用于不同的激酶和共价修饰位于ATP结合位点口袋。这篇综述,对最近的一些多激酶抑制剂的例子进行了报道,集中报道了化学结构,构效关系(SAR)和生物活性。这些抑制剂可以适当的取代以前的药物而用于其他多靶点药物的设计。虚拟的分子对接可能暗示了潜在分子靶点,甚至是联合性的药效基因的结合和筛选方法很可能帮助更多的潜在的多激酶抑制剂的发现。
关键词: ATP-竞争性的,生物活性,杂环化合物,抑制,不可逆的,抑制剂,激酶,多靶点,SAR
Current Medicinal Chemistry
Title:Multi-Kinase Inhibitors
Volume: 22 Issue: 6
Author(s): Laura Garuti, Marinella Roberti and Giovanni Bottegoni
Affiliation:
关键词: ATP-竞争性的,生物活性,杂环化合物,抑制,不可逆的,抑制剂,激酶,多靶点,SAR
摘要: The limitations of many mono-kinase inhibitors can be overcome by agents with multi-target action. An important advantage of targeting more than one kinase, is an increase in potency, due to the synergistic effect. Moreover, this approach can reduce the possibility of developing drug resistance. Several multitarget agents have been designed as single kinase inhibitors and found to be multi-target inhibitors because of the structural homology among the ATP-binding site of kinases. In other cases, these inhibitors have been obtained by optimization of potent individual inhibitors or by combination of selective ligands. Also some irreversible inhibitors act on different kinases and covalently modify the cysteine residues located near the ATP-binding pocket. In this review the most recent examples of multi-kinase inhibitors are reported, focusing on chemical structures, structure-activity relationship (SAR) and biological activity. These inhibitors, suitably substituted, could be used in designing other multitarget agents. Virtual molecular docking would suggest potential targets of molecules, moreover combining pharmacophore combination and screening methods could probably help in the discovery of more potent multikinase inhibitors.
Export Options
About this article
Cite this article as:
Laura Garuti, Marinella Roberti and Giovanni Bottegoni , Multi-Kinase Inhibitors, Current Medicinal Chemistry 2015; 22 (6) . https://dx.doi.org/10.2174/0929867321666141216125528
DOI https://dx.doi.org/10.2174/0929867321666141216125528 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nutrient Regulation of Tumor and Vascular Endothelial Cell Proliferation
Current Cancer Drug Targets Pleiotropic Effects of Cardioactive Glycosides
Current Medicinal Chemistry Stress-Activated MAP Kinase Cascades in Cellular Senescence
Current Medicinal Chemistry Genetic Variations in Telomere Maintenance, with Implications on Tissue Renewal Capacity and Chronic Disease Pathologies
Current Pharmacogenomics and Personalized Medicine The Prodigiosins: A New Family of Anticancer Drugs
Current Cancer Drug Targets Editorial (Hot Topic: Network Pharmacology: An Emerging Field in Cancer Drug Discovery)
Current Drug Discovery Technologies iNOS: A Potential Therapeutic Target for Malignant Glioma
Current Molecular Medicine FOXO Transcription Factors and their Role in Disorders of the Female Reproductive Tract
Current Drug Targets n-3 Polyunsaturated Fatty Acids as Signal Transduction Modulators and Therapeutical Agents in Cancer
Current Signal Transduction Therapy NCRNA Combined Therapy as Future Treatment Option for Cancer
Current Pharmaceutical Design Perinatal Management of Fetal Tumors
Current Pediatric Reviews The Role of Emerging Genomics and Proteomics Technologies in Cancer Drug Target Discovery
Current Cancer Drug Targets Methionine Aminopeptidases as Potential Targets for Treatment of Gastrointestinal Cancers and other Tumors
Current Drug Targets Regulators of the G1 Phase of the Cell Cycle and Neurogenesis
Central Nervous System Agents in Medicinal Chemistry Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers
Current Pharmaceutical Design Target Driven Preclinical Screening for New Antimitotic Chemotherapy Agents
Current Topics in Medicinal Chemistry Impact of Splicing Factor Mutations on Pre-mRNA Splicing in the Myelodysplastic Syndromes
Current Pharmaceutical Design New Entrants into Clinical Trials for Targeted Therapy of Breast Cancer: An Insight
Anti-Cancer Agents in Medicinal Chemistry The Pathophysiological Role of PEDF in Bone Diseases
Current Molecular Medicine FoxO Proteins: Regulation and Molecular Targets in Liver Cancer
Current Medicinal Chemistry